Sign In
Buy ZLAB
$17.17
+0.0200 (+0.117%)
At Close: Jun 03, 2026
Zai Lab: LUNAR Trial Paves Way For New Therapies
11:36pm, Wednesday, 26'th Jul 2023
Zai Lab Limited's recent clinical study results and partnerships demonstrate its commitment to innovation and product development, positioning it as a strong investment prospect in the pharmaceutical
Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
07:30am, Thursday, 20'th Jul 2023
- Company to Host Conference Call and Webcast on August 8, 2023, at 8:00 a.m. ET - Company to Host Conference Call and Webcast on August 8, 2023, at 8:00 a.m. ET
China's NMPA approves Argenx's and Zai Lab's BLA for muscle-weakening disease treatment
11:05am, Friday, 30'th Jun 2023
China's National Medical Products Administration (NMPA) has approved Zai Lab Limited's and Argenx SE's Biologics License Application (BLA) for VYVGART, a treatment for generalised myasthenia gravis (g
Why Shares of Zai Lab Are Dropping Wednesday
11:05am, Wednesday, 07'th Jun 2023
Zai Lab collaborated with NovoCure on a study to treat non-small cell lung cancer. There were some concerns about the validity of the study.
Zai Lab Announces Participation in June Investor Conferences
07:30am, Thursday, 25'th May 2023
SHANGHAI, China and CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company's senior management team will participate
Why Shares of Alibaba, PDD, and Zai Lab Are Rising Today
11:11am, Monday, 22'nd May 2023
Many Wall Street analysts still see an economic recovery playing out in China. President Biden recently said he expects relations with China to improve "very shortly.
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
07:30am, Thursday, 20'th Apr 2023
Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET
1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off
07:45am, Sunday, 26'th Mar 2023
Zai Lab will soon launch a handful of new medicines in China. It's also seeking approval for many of its therapies in the U.S. The company also has enough cash to survive even if some of its clinical
2 Growth Stocks With Incredible Potential in the Next 5 Years
08:30am, Monday, 06'th Mar 2023
Biotech stocks are risky, but high-potential plays can pay off big. Compass Pathways is making progress towards commercializing its first therapy.
3 More Mid-Cap Biotechs The Street Sees Doubling
08:46am, Wednesday, 22'nd Feb 2023
Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based on living organisms that will save and improve the
Zai Lab Limited (ZLAB) Presents at Citi Biotech C-Suite Fireside Chat Series Conference (Transcript)
03:23pm, Tuesday, 14'th Feb 2023
Zai Lab Limited (NASDAQ:ZLAB ) Citi Biotech C-Suite Fireside Chat Series Conference Call February 14, 2023 11:00 AM ET Company Participants Josh Smiley - COO Conference Call Participants Yigal Nochomo
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
07:30am, Thursday, 09'th Feb 2023
Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET
Zai Lab Announces Participation in February Investor Conferences
07:30am, Tuesday, 31'st Jan 2023
SHANGHAI and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company's senior management team will participate in th
Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride
02:56pm, Friday, 27'th Jan 2023
Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.
Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?
03:46am, Monday, 16'th Jan 2023
Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest furth
